




UNIVERSITI PUTRA MALAYSIA

**PREPARATION OF ELLAGIC ACID, HIPPURIC ACID, PERINDOPRIL
ERBUMINE AND CETIRIZINE NANOCOMPOSITES FOR DRUG DELIVERY**

SAMER HASAN AHMAD HUSSEIN AL ALI

FS 2012 10

**PREPARATION OF ELLAGIC ACID, HIPPURIC ACID, PERINDOPRIL
ERBUMINE AND CETIRIZINE NANOCOMPOSITES FOR DRUG
DELIVERY**



By

SAMER HASAN AHMAD HUSSEIN AL ALI



**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

September 2012

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment
of the requirement for the degree of Doctor of Philosophy

**PREPARATION OF ELLAGIC ACID, HIPPURIC ACID, PERINDOPRIL
ERBUMINE AND CETIRIZINE NANOCOMPOSITES FOR DRUG
DELIVERY**

By

SAMER HASAN AHMAD HUSSEIN AL ALI

September 2012

Chair: Prof. Mohd Zobir Bin Hussein, PhD

Faculty: Science

The administration of drugs designed to be given as a single dose rather than multiple doses has recently been made possible using controlled release formulation approach, so that the release of the drugs can be accomplished over long periods of time, enabling an almost constant level of the drug to be maintained in the bloodstream. Moreover, controlled release formulations increase the clinical efficacy of drugs. The introduction of drug nanocomposites as sustained release vehicles has provided a breakthrough in novel drug delivery systems in the field of pharmaceutical technology. Layered double hydroxides (LDHs) are widely used for this purpose. This study aimed at the synthesis of new controlled release formulation of ellagic acid, hippuric acid, perindopril erbumine and cetirizine hydrochloric acid via intercalation of the drug either into zinc-aluminium-, magnesium-aluminium-layered double hydroxides and zinc layered hydroxide, to increase the residence time in the body by sustained release and therefore increase the clinical efficacy.

Eighth nanocomposites were synthesized using zinc layered hydroxide, zinc-aluminium- and magnesium-aluminium-layered double hydroxides. Ellagic acid and hippuric acid were intercalated into zinc layered hydroxides to form ellagic acid, hippuric acid nanocomposites; EAN and HAN, respectively. Perindopril erbumine was also intercalated into zinc-aluminium-layered double hydroxides to form PZAC and PZAE nanocomposites by direct- and ion exchange-method, respectively. In addition, this drug was also intercalated into magnesium-aluminium-layered double hydroxides to form PMAN nanocomposite. In addition, cetirizine was intercalated into zinc layerd hydroxide, zinc-aluminium-layered double hydroxide and magnesium-aluminium-layered double hydroxide to form CETN, CTZAN and CTMAN nanocomposite, respectively.

The basal spacing for the nanocomposite is 10.4, 21.3, 21.7, 19.9, 21.98, 33.9, 31.9 and 31.2 Å for EAN, HAN, PZAE, PZAC, PMAE, CETN, CTZAN and CTMAN , respectively. The result coupled with molecular geometry calculation indicate that the spatial orientation of the drugs in the layered inorganic sheets was monolayer for EAN, HAN and PZAC nanocomposites; and as bilayers for PZAE, PMAE, CETN, CTZAN and CTMAN nanocomposites.

The release of the ellagic acid from its nanocomposite into aqueous solution of Na_3PO_4 and Na_2CO_3 , at 38 hours was 94 % and 69 %, respectively. The release of the drugs from HAN, PZAE, PZAC, PMAE, CETN, CTZAN and CTMAN nanocomposites at pH 7.4 is 3780, 1000, 1263, 5000, 4980, 600 and 2980 minutes, respectively, compared to 1260, 1100, 1020, 1000, 4320, 600 and 750 minutes, respectively at pH 4.8. This result indicates sustained release of the drugs from their

respective nanocomposites, and therefore these nanocomposites have good potential to be used as controlled-release formulation of the drugs.

In vitro bioassay study for EAN nanocomposite, the result showed that EAN has a mild effect on the hepatocytes cells, similar to its counterpart, the free EA. HAN has synergistic properties with tamoxifen toward a HepG2 cells line, with an IC₅₀ value of 0.35 compared to hippurate. In the antiproliferative assay, the ratio of viable cells account for cells treated by the combination of tamoxifen with HAN to untreated cells was sharply reduced to 66 % and 13 % after 24 and 72 hours, respectively.

The angiotensin converting enzyme (ACE) inhibition activity of perindopril in PZAE, PZAC and PMAE nanocomposites was determined in vitro. The three formulations shows inhibition with 70.6, 70.1 and 55.4 % for PMAE, PZAE and PZAC nanocomposites, respectively. The MgAl-LDH shows mild potent ACE inhibitory activity with 5.6 % decreased in ACE activity, while the ZnAl-LDH did not show any effect toward ACE enzyme.

Release of histamine from RBL-2H3 cells was found to be more sensitive to the intercalated cetirizine in the CETN nanocomposite compared to its free counterpart with inhibition of 56 % and 29 %, respectively at 62.5 ng/ml. The inhibition of histamine by the free cetirizine is higher than the intercalated cetirizine into CTZAN and CTMAN nanocomposites.

This study showed that the formation of organic-inorganic nanocomposite materials of ellagic acid, hippuric acid, perindopril erbumine and cetirizine as organic guests and zinc-aluminium-layered double hydroxide, magnesium-aluminium-layered

double hydroxides and zinc-layered hydroxide as hosts can be successfully accomplished. All the nanocomposites show controlled release property of the organic guests, the drug actives, and therefore are useful for drug delivery systems.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PENYEDIAAN NANOKOMPOSIT ASID ELAGIK, ASID HIPPURIK,
PERINDOPRIL ERBUMIN DAN SETRIZIN UNTUK PENGHANTARAN
UBAT**

Oleh

SAMER HASAN AHMAD HUSSEIN AL ALI

September 2012

Pengerusi: Profesor Mohd Zobir bin Hussein, PhD

Fakulti: Sains

Penyampaian ubat yang direka untuk diberikan melalui satu dos berbanding beberapa dos telah direalisasikan melalui formulasi pelepasan terkawal. Dengan itu, pelepasan ubat dapat dilakukan dalam tempoh yang panjang dan seterusnya membolehkan kadar ubat yang malar dalam saluran darah. Selain daripada itu, formulasi pelepasan terkawal turut meningkatkan keberkesanan klinikal ubat. Pengenalan nanokomposit ubat sebagai agen pelepasan berterusan adalah merupakan suatu kaedah penyampaian ubat yang novel dalam bidang teknologi farmaseutikal. Hidroksida berlapis ganda (LDH) telah digunakan secara meluas untuk tujuan tersebut. Kajian ini adalah merangkumi sintesis formulasi pelepasan terkawal bagi ubat-ubatan seperti asid elagik, asid hipurik, perindopril erbumin dan setrizin melalui interkalasi ke dalam zink-aluminium-, magnesium-aluminium-LDH dan hidroksida belapis zink. Kaedah yang digunakan adalah bertujuan untuk meningkatkan tempoh kehadiran ubat di dalam badan melalui pelepasan berterusan daripada nanokompositnya.

Dalam kajian ini, lapan nanokomposit telah disintesis menggunakan hidroksida berlapis zink, zink-aluminium- dan magnesium-aluminium-LDHs sebagai perumah.

Asid elagik dan asid hipurik telah diinterkalasi ke dalam hidroksida berlapis zink bagi menghasilkan nanokomposit asid elagik (EAN) dan nanokomposit asid hipurik (HAN). Perindopril erbumin telah diinterkalasi ke dalam zink-aluminium LDH melalui kaedah terus dan kaedah pertukaran ion masing-masing bagi menghasilkan PZAC dan PZAE. Selain daripada itu, ubat ini turut diinterkalasi ke dalam magnesium-aluminium LDH untuk menghasilkan nanokomposit PMAN. Seterusnya setrizin telah juga diinterkalasikan ke dalam hidroksida berlapis zink, zink-aluminium- dan magnesium-aluminium-LDH masing-masing bagi penghasilan nanokomposit CETN, CTZAN dan CTMAN.

Jarak basal bagi semua nanokomposit EAN, HAN, PZAE, PZAC, PMAE, CETN, CTZAN dan CTMAN adalah 10.4, 21.3, 21.7, 19.9, 21.98, 33.9, 31.9 dan 31.2 Å. Keputusan ini bersama dengan pengiraan geometri molekul menunjukkan bahawa orientasi ruang bagi tetamu dalam nanokomposit EAN, HAN dan PZAC adalah ekalapis sementara tetamu dalam nanokomposit PZAE, PMAE, CETN, CTZAN dan CTMAN mempunyai orientasi ruang yang terdiri daripada dua lapisan.

Pelepasan asid elagik daripada nanokomposit selepas 38 jam adalah 94% dalam larutan akueous Na_3PO_4 dan 69% bagi Na_2CO_3 . Pelepasan ubat pada pH 7.4 daripada nanokomposit HAN, PZAE, PZAC, PMAE, CETN, CTZAN dan CTMAN berlaku masing-masing selepas 3780, 1000, 1263, 5000, 4980, 600 dan 2980 minit. Manakala pada pH 4.8, pelepasan ubat dari semua nanokomposit yang tersenarai di atas masing-masing berlaku selepas 1260, 1100, 1020, 1000, 4320, 600 dan 750 minit.

Kajian menggunakan bioassay *in vitro* bagi nanokomposit asid elagik, EAN menunjukkan bahawa ianya memberikan kesan yang sedikit kepada sel hepatosit iaitu hampir menyamai asid elagik bebas, EA. Manakala nanokomposit asid hipurik,

HAN mempunyai ciri-ciri bersinergi dengan tamoxifen terhadap sel-sel HepG2 dengan nilai IC₅₀ 0.35 berbanding dengan hippurat. Dalam assay antiproliferative, nisbah sel hidup adalah sama dengan sel yang telah dicampur dengan kombinasi tamoxifen dan HAN berbanding sel bebas. Nisbah sel hidup ini berkurangan sehingga 66% selepas 24 jam manakala jumlah pengurangan adalah 13% selepas 72 jam.

Penghalangan aktiviti enzim penukaran angiotensin (ACE) oleh perindopril bagi nanokomposit PZAE, PZAC dan PMAE telah ditentukan secara *in vitro*. Ketiga-tiga nanokomposit iaitu PMAE, PZAE and PZAC masing-masing menghalang aktiviti enzim ACE sebanyak 70.6, 70.1 dan 55.4%.

Pelepasan histamin dari sel RBL-2H3 didapati lebih sensitif terhadap setrizin yang diinterkalasi di dalam nanokomposit CETN berbanding setrizin bebas. Peratusan halangan pembebasan histamin pada kepekatan 62.5 ng/ml bagi nanokomposit CETN dan setrizin bebas masing-masing adalah 56% dan 29%. Manakala, kadar halangan pembebasan histamin oleh setrizin bebas adalah lebih tinggi berbanding setrizin yang diinterkalasi ke dalam nanokomposit CTZAN dan CTMAN.

Kajian ini menunjukkan bahawa pembentukan bahan nanokomposit organik-inorganik daripada sebatian organik seperti asid elagik, asid hipurik, perindopril erbumin dan setrizin dengan hos inorganic zink-aluminium LDHs, magnesium-aluminium LDHs dan hidroksida berlapis zink telah dapat dilaksanakan dengan jayanya. Semua nanokomposit tersebut menunjukkan ciri-ciri pelepasan terkawal bahan organik bagi bahan aktif ubatan, dan ini menjadikan ianya berguna bagi sistem penyampaian ubat.

ACKNOWLEDGEMENT

In the name of Allah, the Most Gracious, the Most Merciful. Only with his blessings and guidance, help that can complete this thesis. A special thank goes to my supervisor, Professor Dr. Mohd Zobir bin Hussein for the supervision and support given which truly help the progression and smoothness of this work, the cooperation is indeed much appreciated. I would also like to thank my supervisor committee members, Professor Dr. Zulkarnain bin Zainal and Professor Dr. Mohammad Nazrul Hakim for their help and suggestions. My grateful thanks to Professor Dr. Maznah Ismail and Mothannah Al-Qubaisi for their help in cytotoxicity study and suggestions. I am truly indebted and thankful for Universiti Putra Malaysia for the International Graduate Research Fellowship (IGRF). My sincere thanks to all the university officers especially, Mrs Rosnani Amiruddin and En. Kadri, thank to the lab-mates; Abdullah Ahmad, Sumayah, Shazlyn Tumirah, Haizum, Bullo Sifollah and Nur Suzariana. I owed my deepest gratitude for my mother, which prays daily to Allah Subhanahu Wa ta'ala so that I can complete my work. Her emotional support and endless pure love are greatly appreciated. I will never forget my father who had wished me since my childhood to achieve this stage of education. I would also like to record my gratitude to my wife, Mai. Her love, support and patience have lead me to a great success in this work. I would like to dedicate this thesis to her. My grateful thanks are also going to our paradise birds; Khalid and Omar, my sons, who have spent many days with my wife to allow me focus on my work. I am deeply sorry that I cannot spend time with them. I would like to thank my family members, especially my brothers; Sameer, Ahmad, Sami, and Mohammad, and my sisters; Sana'a and Maha for your support. I also like to thank Abed Al-Rahman, my wife family and

Nasuh, my uncle family for encouraging me to pursue this degree. Last but not least my thanks and appreciation to my brother-in-law, Mr. Maher for his support during my study.



I certify that a Thesis Examination Committee has met on 28 September 2012 to conduct the final examination of Samer Hasan Ahmad Hussein Al Ali on his thesis entitled "**PREPARATION OF ELLAGIC ACID, HIPPURIC ACID, PERINDOPRIL ERBUMINE AND CETIRIZINE NANOCOMPOSITES FOR DRUG DELIVERY**" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Examination Committee are as follows:

MANSOR B HJ AHMAD, PhD

Associate Professor

Faculty of Science

Universiti Putra Malaysia

(Chairman)

ABDUL HALIM BIN ABDULLAH, PhD

Associate Professor

Faculty of Science

Universiti Putra Malaysia

(Internal Examiner)

NOR AZAH BINTI YUSOF, PhD

Associate Professor

Faculty of Science

Universiti Putra Malaysia

(Internal Examiner)

VICENTE RIVES, PhD

Professor

Department of Inorganic Chemistry

University of Salamanca

Spain

(External Examiner)

SEOW HENG FONG, PhD

Professor and Deputy Dean

School of Graduates Studies

Universiti Putra Malaysia

Date:13 December 2012

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of **Doctor of Philosophy**. The members of the Supervisory Committee were as follows:

Mohd. Zobir bin Hussein, PhD

Professor

Faculty of Science

Universiti Putra Malaysia

(Chairman)

Zulkarnain bin Zainal, PhD

Professor

Faculty of Science

Universiti Putra Malaysia

(Member)

Mohammad Nazrul Hakim, PhD

Professor

Faculty of Medicine and Health Science

Universiti Putra Malaysia

(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean

School of Graduates Studies

Universiti Putra Malaysia

Date:

DECLARATION

I declare that the thesis is my original work except for quotations and citations, which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.




TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	vi
ACKNOWLEDGEMENT	ix
APPROVAL	xi
DECLARATION	xiii
CHAPTER	
1 INTRODUCTION	
1.1 Background of study	1
1.2 Problem Statement	2
1.3 Objectives	5
1.4 Significance of study	6
2 LITERATURE REVIEW	
2.1 Historical Background	7
2.2 Layered double hydroxide	8
2.2.1 Structure of layered double hydroxide	8
2.2.2 Chemical composition of inorganic layers in layered double hydroxides	9
2.2.3 Interlayer spacing composition of layered double hydroxide	13
2.2.4 Preparation of layered double hydroxides	16
2.3 Layered hydroxide salts	21
2.3.1 Structure of layered hydroxide salts	21
2.3.2 Chemical composition of layers in layered hydroxide salts	24
2.3.3 Anions in the Interlayer spacing	25
2.3.4 Preparation of layered hydroxide salts	26
2.4 Applications of layered double hydroxides and layered hydroxide salts	30
2.5 Drug delivery and cellular uptake	32
2.5.1 Distinctive features of layered double hydroxides from others nanoparticles in drug delivery	32
2.5.2 Cellular Uptake of layered double hydroxides	34
2.5.3 Layered double hydroxides nanolayers as drug delivery vehicle for human therapeutics	37
2.6 Sustained-release	39
2.6.1 Factors effecting on the rate of sustained-release	40
2.6.2 Burst release	42
2.6.3 Kinetic models	42
2.7 Cytotoxicity assay	45
2.7.1 Methyl tetrazolium assay	46
2.7.2 Trypan blue exclusion assay	47
2.7.3 Total protein content assay	47

3 METHODOLOGY

3.1	Materials	49
3.2	Synthesis of layered double hydroxides and zinc layered hydroxide	50
3.2.1	Zinc-aluminium-nitrate-layered double hydroxide	50
3.2.2	Magnesium-aluminium-nitrate-layered double hydroxide	50
3.2.3	Zinc-nitrate-layered hydroxide	50
3.3	Synthesis of nanocomposites	51
3.3.1	Synthesis of ellagic acid-zinc layered hydroxides nanocomposite	51
3.3.2	Synthesis of hippuric acid-zinc layered hydroxides nanocomposite	51
3.3.3	Synthesis of perindopril erbumine-zinc-aluminium-layered double hydroxides nanocomposite by ion-exchange method	52
3.3.4	Synthesis of perindopril erbumine-zinc-aluminium-layered double hydroxides nanocomposite by coprecipitation method	52
3.3.5	Synthesis of perindopril erbumine magnesium - aluminium-layered double hydroxides nanocomposite by ion-exchange method	52
3.3.6	Synthesis of cetirizine-zinc layered hydroxides nanocomposite	53
3.3.7	Synthesis of cetirizine-zinc-aluminium-layered double hydroxides nanocomposite by ion-exchange method	54
3.3.8	Synthesis of cetirizine-magnesium-aluminium-layered double hydroxides nanocomposite by ion-exchange method	54
3.4	Physico-chemical analysis and characterizations	55
3.5	Cytotoxicity assay	59
3.5.1	Cytotoxicity assay for ellagic acid nanocomposite by using lactate dehydrogenase activity	59
3.5.2	Cytotoxicity assay for hippuric acid nanocomposite	60
3.5.3	Antiproliferation assay for hippuric acid nanocomposite	60
3.5.4	Cytotoxicity assay for perindopril erbumine nanocomposites	61
3.5.5	Cytotoxicity assay for cetirizine nanocomposites	61
3.6	Angiotensin-Converting Enzyme inhibition properties of a perindopril erbumine	62
3.7	Effect of cetirizine-nanocomposites and the nanoparticles on histamine release from Rat basophilic leukemia cells	63

4 Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent	64
Copyright permission	91
5 Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines	92
Copyright permission	123
6 Controlled release and angiotensin-converting-enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite	124
Copyright permission	157
7 Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme	158
Copyright permission	189
8 Controlled-release formulation of antihistamine based on cetirizine-zinc layered hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) cells	190
Copyright permission	221
9 In vitro Inhibition of Histamine Release Behaviour of Cetirizine Intercalated into Zn/Al and Mg/Al Layered Double Hydroxides	222
Copyright permission	253
10 CONCLUSIONS AND RECOMMENDATION FOR FURTHER RESEARCH	254
REFERENCES	260
APPENDICES	276
BIODATA OF STUDENT	283
PUBLICATIONS, CONFERENCES AND WORKSHOPS	284